We’ve Got a Company – ContraVac

The organizers of CVG’s LiveFire! ™ have announced one of five companies to pitch to a panel of angel investors at the inaugural VT KnowledgeWorks Entrepreneurship Summit - ContraVac.

SpermCheck Vasectomy home test from ContraVac The mission of ContraVac, located in Charlottesville, Virginia, is "To provide leadership, education and innovation in male reproductive healthcare with revolutionary products that promise accuracy, efficiency and accessibility."

From Ed Leary, President and Chief Financial Officer, ContraVac:

"We are very pleased to be selected to present at CVG Live Fire. This event is an excellent opportunity for the investment community to learn more about ContraVac and the SpermCheck products - including the commercial launch of SpermCheck Vasectomy in April 2009 - the successful completion of SpermCheck Fertility clinical trials, and the investment opportunities in ContraVac."

You can watch ContraVac – and four other to-be-announced companies - present to angel investors by registering for the inaugural VT KnowledgeWorks Entrepreneurship Summit which will be held on Thursday, April 2, 2009, in Blacksburg, Virginia.  

***

Thanks to Ed Leary for this additional information about ContraVac:

ContraVac, located in Charlottesville, Virginia, develops products for male reproductive healthcare in cooperation with the Center for Research in Contraceptive and Reproductive Health at the University of Virginia which is directed by ContraVac’s founder, Dr. John Herr, Ph.D. ContraVac is dedicated to developing and commercializing research discoveries into innovative diagnostics for male reproductive health care. 

Our Products and Markets

ContraVac’s family of SpermCheck products have been developed to meet the needs of millions of men who seek actionable information about their fertility health but wish to test themselves at home to avoid the inconvenience and indignities associated with traditional semen analysis. SpermCheck Vasectomy, available in April 2009, is calibrated to detect extremely low numbers of sperm and will be used by recently vasectomized men to determine when their sperm counts have fallen below fertile levels. SpermCheck Fertility, expected to be commercially available in August 2009, is for use primarily by men in couples planning to conceive, or currently attempting to conceive, to determine if fertile concentrations of sperm are present in their semen.

Comments

  1. Over twenty years ago I tried desperately, then dejectedly, then, ultimately, unsuccessfully, to conceive a child.

    The tools that today from your company would be termed biomedical and biotechnology innovations would have been of great personal, human, and humane value to me twenty years ago.

    Thanks to ContraVac's innovations, I am very glad that others will have some privacy over this very private issue.

Speak Your Mind

*